COMMUNIQUÉS West-GlobeNewswire

Beta Bionics to Announce Second Quarter 2026 Financial Results on July 29, 2026
01/07/2026
IRVINE, Calif., July 01, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release its second [...]
Abivax annonce la fixation du prix de l’Offre au public largement sursouscrite de 800 M$ (702 M€) d’American Depositary Shares
01/07/2026
Abivax annonce la fixation du prix de l’Offre au public largement sursouscrite de 800 M$ (702 M€) d’American Depositary Shares Le montant de l'offre a été augmenté de 600 M$ à 800 M$ , à un prix de 125,00 $ par ADS , [...]
Abivax Announces Pricing of Oversubscribed and Upsized $800M (€702M) Public Offering of American Depositary Shares
01/07/2026
Abivax Announces Pricing of Oversubscribed and Upsized $800M (€702M) Public Offering of American Depositary Shares Upsized offering increased from the previously announced $600M to $800M at $125.00 per ADS , priced at a [...]
Artelo Biosciences Announces New Data Supporting ART26.12 as a Potential First-in-Class Therapy for Chronic Pain associated with Spinal Cord Injury
01/07/2026
The nonclinical study conducted at Stony Brook University adds to substantial evidence of activity across multiple animal models of neuropathic pain SOLANA BEACH, Calif., July 01, 2026 (GLOBE NEWSWIRE) -- Artelo [...]
SERB Pharmaceuticals Completes Acquisition of European and MENA Rights to Idefirix® (imlifidase) from Hansa Biopharma
01/07/2026
BRUSSELS, July 01, 2026 (GLOBE NEWSWIRE) -- SERB Pharmaceuticals, a global specialty pharmaceutical company designed to address rare and urgent conditions, today announced that it has completed the acquisition of [...]
Oxford-Harrington Rare Disease Centre Strengthens Rare Childhood Cancer Programme Through Appointment of New Little Princess Trust Professor of Paediatric Oncology
01/07/2026
Professor Isidro Cortés-Ciriano, a n internationally recognised scientist with extensive experience in childhood cancer research, will accelerate Oxford-Harrington’s mission to translate discoveries into new therapies [...]
Alvotech further strengthens liquidity by securing term loan facility of $75 million
01/07/2026
— $75 million additional term loan facility maturing December 31, 2027, led by GoldenTree Asset Management — Follows recent $165m equity raise strengthening cash position — Including equity financing and undrawn loan [...]
Alvotech further strengthens liquidity by securing term loan facility of $75 million
01/07/2026
$75 million additional term loan facility maturing December 31, 2027, led by GoldenTree Asset Management Follows recent $165m equity raise strengthening cash position Including equity financing and undrawn loan facility [...]
AB Science : Résultats de l'Assemblée Générale Mixte du 30 juin 2026
01/07/2026
COMMUNIQUE DE PRESSE RESULTATS DE L’ASSEMBLEE GENERALE MIXTE DU 30 JUIN 2026 Paris, 1 er juillet 2026, 10h Les actionnaires de la société AB Science se sont réunis en Assemblée Générale Mixte, le mardi 30 juin 2026 à [...]
Press Release: Availability of the aide-mémoire for Q2 2026 results
01/07/2026
Availability of the aide-mémoire for Q2 2026 results Paris, France – July 1, 2026 . Sanofi announced today the availability of the aide-mémoire for Q2 2026 results on the "Investors" page of sanofi.com: Second quarter [...]
AB Science announces the successful completion of a EUR 2.3 million private placement
01/07/2026
PRESS RELEASE AB SCIENCE ANNOUNCES THE SUCCESSFUL COMPLETION OF A EUR 2.3 MILLION PRIVATE PLACEMENT Paris, July 1 st , 2026, 8am AB Science S.A. (the “ Company ” or “ AB Science ”, Euronext – FR0010557264 – AB) [...]
AB Science annonce le succès d’un placement privé de 2,3 millions d’euros
01/07/2026
COMMUNIQUE DE PRESSE AB SCIENCE ANNONCE LE SUCCES D’UN PLACEMENT PRIVE DE 2,3 MILLIONS D’EUROS Paris, 1 er juillet 2026, 8h AB Science S.A. (la “ Société ” ou “ AB Science ”, Euronext – FR0010557264 – AB) annonce [...]
Eurobio Scientific finalise l'acquisition de la division « Lab Products » de CareDX dédiée à la transplantation
01/07/2026
EUROBIO SCIENTIFIC FINALISE L'ACQUISITION DE LA DIVISION « LAB PRODUCTS 1 » DE CAREDX DÉDIÉE À LA TRANSPLANTATION Accélération du plan stratégique d’Eurobio visant à devenir un leader du diagnostic moléculaire in vitro [...]
Eurobio Scientific finalizes the acquisition of CareDX’s transplant Lab Product division
01/07/2026
EUROBIO SCIENTIFIC FINALIZES THE ACQUISITION OF CAREDX’s TRANSPLANT LAB PRODUCT DIVISION Acceleration of Eurobio’s strategic plan to become an in-vitro molecular diagnostics (“IVD”) leader Creation of a global leading [...]
Nicox’s NCX 470 New Drug Application Submitted in the United States by Kowa, with Associated €3 million Milestone Payment
01/07/2026
Press Release Nicox’s NCX 470 New Drug Application Submitted in the United States by Kowa, with Associated €3 million Milestone Payment NCX 470 New Drug Application (NDA) submitted to the U.S. Food and Drug [...]
Nicox : Demande d’autorisation de mise sur le marché de NCX 470 soumise aux Etats-Unis par Kowa, avec un paiement d’étape de 3 millions d’euros associé
01/07/2026
Communiqué de presse Nicox : Demande d’autorisation de mise sur le marché de NCX 470 soumise aux Etats-Unis par Kowa, avec un paiement d’étape de 3 millions d’euros associé La demande d’autorisation de mise sur le [...]
Ipsen va acquérir Memo Therapeutics AG, élargissant son portefeuille de maladies rares grâce à l’ajout d’un anticorps premier de sa classe ciblant le polyomavirus BK
01/07/2026
Acquisition centrée sur le potravitug, un anticorps monoclonal premier de sa classe au stade clinique, ciblant le polyomavirus BK L’ensemble des données issues de l’essai de phase II SAFE KIDNEY II soutient le lancement [...]
Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio
01/07/2026
Acquisition focused on clinical-stage program potravitug, a first-in-class BK polyomavirus monoclonal antibody Totality of evidence from the Phase II SAFE KIDNEY II trial supports initiation of pivotal Phase II/III [...]
Abivax announces temporary trading halt of its ordinary shares on Euronext Paris
01/07/2026
Abivax announces temporary trading halt of its ordinary shares on Euronext Paris PARIS, France, July 1, 2026 – 07:30 a.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“ Abivax ” or the “ Company ”), a [...]

Pages